Zymergen completed the acquisition of ALSP-backed Lodo Therapeutics

Zymergen, a biotechnology company, completed the acquisition of Lodo Therapeutics Corporation, an ALSP-backed biotechnology firm. Financial terms were not disclosed. “The Lodo Therapeutics metagenomic platform complements Zymergen’s discovery efforts by expanding their natural product discovery capabilities,” Sean Brady, Ph.D., Lodo Therapeutics Co-Founder.